Page 100 - 《中国药房》2023年13期
P. 100

参考文献                                                [13]  HEINRICH M C,JONES R L,VON MEHREN M,et al.
          [ 1 ]  SERRANO C. New treatments in advanced gastrointesti‐  Avapritinib in advanced PDGFRA D842V-mutant gastro‐
                                                                   intestinal stromal tumour (NAVIGATOR):a multicentre,
               nal  stromal  tumor[J].  Curr  Opin  Oncol,2021,33(4):
               323-328.                                            open-label,phase 1 trial[J]. Lancet Oncol,2020,21(7):
          [ 2 ]  SHARMA A K,KIM T S,BAUER S,et al. Gastrointesti‐  935-946.
               nal stromal tumor:new insights for a multimodal approach  [14]  BENSON A B,VENOOK A P,AL-HAWARY M M,et al.
                                                                   Colon  cancer,version  2.2021,NCCN  clinical  practice
               [J]. Surg Oncol Clin N Am,2022,31(3):431-446.
                                                                   guidelines  in  oncology[J].  J  Natl  Compr  Canc  Netw,
          [ 3 ]  FERNÁNDEZ J A,FERRERAS D,RUIZ-MANZANERA
                                                                   2021,19(3):329-359.
               J J,et al. Characteristics and prognosis of jejunoileal ga-
                                                              [15]  WANG T,ZENG X Y,YANG W C,et al. Clinicopatho‐
               strointestinal stromal tumours (GISTs) in the era of ima‐
                                                                   logical characteristics and prognosis of patients with spo‐
               tinib:a  comparative  study  with  gastric  GISTs[J].  Clin
                                                                   radic  multiple  primary  gastrointestinal  stromal  tumors[J].
               Transl Oncol,2021,23(7):1368-1376.
                                                                   Chin J Gastrointest Surg,2021,24(9):783-788.
          [ 4 ]  SHI H P,WANG Z Q,FAN Z Y,et al. Analysis and com‐
                                                              [16]  BELOW  S,MICHAELIS  L  C.  Avapritinib  in  the  treat‐
               parison  of  the  clinical  features  and  prognosis  between
                                                                   ment of systemic mastocytosis:an update[J]. Curr Hema‐
               extra-gastrointestinal stromal tumors and duodenal gastro‐
                                                                   tol Malig Rep,2021,16(5):464-472.
               intestinal  stromal  tumors[J].  Chin  J  Gastrointest  Surg,
                                                              [17]  GOTLIB J,REITER A,RADIA D H,et al. Efficacy and
               2019,22(9):856-860.
                                                                   safety  of  avapritinib  in  advanced  systemic  mastocytosis:
          [ 5 ]  BAUER S,GEORGE S,VON MEHREN M,et al. Early
                                                                   interim analysis of the phase 2 PATHFINDER trial[J]. Nat
               and  next-generation  KIT/PDGFRA  kinase  inhibitors  and
                                                                   Med,2021,27(12):2192-2199.
               the future of treatment for advanced gastrointestinal stro‐
                                                              [18]  DHILLON S. Avapritinib:first approval[J]. Drugs,2020,
               mal tumor[J]. Front Oncol,2021,11:672500.
                                                                   80(4):433-439.
          [ 6 ]  ALZOFON  N,JIMENO A. Avapritinib  for  metastatic  or
                                                              [19]  VALENT  P,AKIN  C,HARTMANN  K,et  al.  Updated
               unresectable gastrointestinal stromal tumors[J]. Drugs To‐
                                                                   diagnostic criteria and classification of mast cell disorders:
               day,2020,56(9):561-571.
                                                                   a consensus proposal[J]. Hemasphere,2021,5(11):e646.
          [ 7 ]  中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学
                                                              [20]  REITER A,SCHWAAB J,DEANGELO D J,et al. Effi‐
               会 (CSCO)胃肠间质瘤诊疗指南2021[M]. 北京:人民卫
                                                                   cacy  and  safety  of  avapritinib  in  previously  treated  pa‐
               生出版社,2021:64.
                                                                   tients with advanced systemic mastocytosis[J]. Blood Adv,
          [ 8 ]  DEANGELO  D  J,RADIA  D  H,GEORGE  T  I,et  al.
                                                                   2022,6(21):5750-5762.
               Safety  and  efficacy  of  avapritinib  in  advanced  systemic   [21]  KANG Y K,GEORGE S,JONES R L,et al. Avapritinib
               mastocytosis:the phase 1 EXPLORER trial[J]. Nat Med,  versus  regorafenib  in  locally  advanced  unresectable  or
               2021,27(12):2183-2191.                              metastatic  GI  stromal  tumor:a  randomized,open-label
          [ 9 ]  张科,邵佳,孙璇,等. 基于FAERS的二肽基肽酶4抑制                      phase Ⅲ study[J]. J Clin Oncol,2021,39(28):3128-3139.
               剂相关不良事件信号挖掘[J]. 中国药房,2022,33(24):              [22]  GARCÍA CARIDE S,MARQUINA G,DÍAZ VALLE D.
               3015-3019.                                          Preseptal cellulitis,intraocular inflammatory reaction and
          [10]  司方莹,薛莹,卢晓静,等. 基于真实世界对托法替布上                         corneal persistent epithelial defect as side effects of avapri‐
               市后不良事件信号的挖掘与分析[J]. 中国医院药学杂                          tinib[J]. Anticancer Drugs,2021,32(10):1127-1130.
               志,2022,42(22):2407-2410,2420.                  [23]  HENRIQUES-ABREU  M,SERRANO  C.  Avapritinib  in
          [11]  JONES  R  L,SERRANO  C,VON  MEHREN  M,et  al.      unresectable  or  metastatic  gastrointestinal  stromal  tumor
               Avapritinib  in  unresectable  or  metastatic  PDGFRA   with  PDGFRA  exon  18  mutation:safety  and  efficacy[J].
               D842V-mutant  gastrointestinal  stromal  tumours:long-  Expert Rev Anticancer Ther,2021,21(10):1081-1088.
               term  efficacy  and  safety  data  from  the  NAVIGATOR   [24]  MAZZOCCA A,NAPOLITANO A,SILLETTA M,et al.
               phase Ⅰ trial[J]. Eur J Cancer,2021,145:132-142.    New frontiers in the medical management of gastrointesti‐
          [12]  JOSEPH C P,ABARICIA S N,ANGELIS M A,et al. Op‐     nal stromal tumours[J]. Ther Adv Med Oncol,2019,11:
               timal  avapritinib  treatment  strategies  for  patients  with   1758835919841946.
               metastatic or unresectable gastrointestinal stromal tumors   (收稿日期:2022-11-24  修回日期:2023-06-19)
               [J]. Oncologist,2021,26(4):e622-e631.                                              (编辑:胡晓霖)









          · 1626 ·    China Pharmacy  2023 Vol. 34  No. 13                            中国药房  2023年第34卷第13期
   95   96   97   98   99   100   101   102   103   104   105